EyeYon Medical Ltd.

EyeYon Medical Ltd. is focused on developing innovative ophthalmic solutions to treat corneal conditions, aiming to enhance and restore vision through its advanced medical technologies. Founded in 2011 in Israel, EyeYon Medical Ltd. specializes in ophthalmic products that address corneal health issues.

The company was established by Nahum Ferera, who also serves as the CEO. EyeYon has undergone strategic growth and has engaged in 6 total deals, with its most recent funding round occurring on March 15, 2021. During this Series C round, the company raised USD 25. 00 mn from investors including Global Strategic Investment Fund Corporation and China Resources Capital Management, among others.

This funding represents the total amount raised by the company to date. EyeYon Medical specializes in innovative ophthalmic solutions aimed at treating corneal conditions, with a focus on preserving and restoring vision for patients worldwide. The company's flagship products include EndoArt®, the first synthetic implant designed to treat corneal edema, and Hyper-CL™, a therapeutic contact lens that enhances the bioavailability of topical medications for various corneal disorders. EndoArt® functions as an artificial layer that minimizes fluid transfer from the aqueous humor to the corneal stroma, effectively addressing endothelial failure and reducing reliance on human donor tissue.

Hyper-CL™ serves as a novel drug repository lens, which prolongs the availability of antimicrobial agents directly over the affected cornea, facilitating faster healing in conditions such as bacterial keratitis. These products are utilized by ophthalmic surgeons in various global markets, including the United States, Europe, and Asia, and serve a diverse client base, including hospitals, medical centers, and eye clinics. EyeYon Medical's revenue model primarily revolves around B2B transactions with healthcare providers and medical institutions that require advanced ophthalmic treatments. The company engages in direct sales of its proprietary products, namely EndoArt® and Hyper-CL™, to surgical centers and eye care professionals.

Each product is sold as a one-time purchase, with the potential for repeat orders based on patient needs and treatment outcomes. The firm collaborates with hospitals and medical practitioners, establishing partnerships that enhance distribution across geographical markets, including significant regions in Europe, Asia, and the Americas. Given the nature of the healthcare industry, transactions are structured around direct sales agreements, with pricing reflective of the innovative technology and clinical benefits provided by their flagship offerings. In March 2021, EyeYon Medical Ltd.

raised USD 25. 00 mn in Series C financing to expand its clinical trials for its flagship product, EndoArt®. The company is focused on launching new products aimed at treating corneal conditions and plans to target new geographic markets to further its reach. Specific markets for expansion include regions in Europe and Asia, with the intent to enhance accessibility to its innovative ophthalmic solutions.